ACY-738

ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC50 of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC50s of 94, 128, and 218 nM.

Product Specifications

CAS Number

[1375465-91-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ACY-738.html

Purity

99.92

Solubility

DMSO : ≥ 32 mg/mL

Smiles

O=C(NO)C(C=N1)=CN=C1NC2(CC2)C3=CC=CC=C3

Molecular Formula

C14H14N4O2

Molecular Weight

270.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Jochems J, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014 Jan;39 (2) :389-400.|[2]Regna NL, et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan;162:58-73.|[3]Mithraprabhu S, et al. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol. 2013 Aug;162 (4) :559-62.